Edition:
United States

Biotechnology & Medical Research

Page 2

BiondVax Phase 2b European Trial: Last Patient Out

Wednesday, 21 Sep 2016 08:45am EDT

BiondVax Pharmaceuticals Ltd : Last participant in a European phase 2b clinical trial of M-001, its universal flu vaccine candidate, has completed final visit .Top line results expected in coming months.

4SC appoints Jason Loveridge as new CEO

Wednesday, 21 Sep 2016 08:33am EDT

4SC AG :Jason Loveridge appointed new CEO of 4SC.

Bluebird Bio's LentiGlobin investigational gene therapy accepted into Europen Medicines Agency's PRIME program

Wednesday, 21 Sep 2016 08:30am EDT

Bluebird Bio Inc :LentiGlobin(TM) investigational gene therapy for transfusion-dependent beta-thalassemia accepted into European Medicines Agency's PRIME program.

Redhill Biopharma Ltd and IntelGenx announce RIZAPORT commercialization with pharmatronic co.

Wednesday, 21 Sep 2016 08:00am EDT

Redhill Biopharma Ltd : Redhill Biopharma and IntelGenx announce RIZAPORT commercialization term sheet with Pharmatronic Co. for Korea . Pursuant to signing of definitive agreement, Co will grant Pharmatronic exclusive rights to commercialize RIZAPORT in South Korea . Under term sheet, Co and IntelGenx are to receive an upfront payment and will be eligible to receive additional milestone payments .Financial terms of term sheet were not disclosed.

Court approves SIGA Technologies proposed deal under Chapter 11

Wednesday, 21 Sep 2016 07:00am EDT

Siga Technologies Inc :Court approved co's proposed deal under Chapter 11 plan; co to pay PharmAthene full balance of outstanding judgment on/before Nov 30.

Court approves SIGA Technologies proposed deal under Chapter 11

Wednesday, 21 Sep 2016 07:00am EDT

Siga Technologies Inc :Court approved co's proposed deal under Chapter 11 plan; co to pay PharmAthene full balance of outstanding judgment on/before Nov 30.

Insys Therapeutics announces CEO succession plan

Wednesday, 21 Sep 2016 07:00am EDT

Insys Therapeutics Inc : Insys Therapeutics announces CEO succession plan . Board has appointed a special committee, comprised of independent board members to conduct search for company's next CEO . Insys Therapeutics inc says company's board has initiated a search to identify a candidate to succeed John N. Kapoor as President and CEO .Kapoor will continue to serve as president and CEO until his replacement is appointed.

Syngene International buys systems biology, pharma services practice of Strand Life Sciences

Wednesday, 21 Sep 2016 06:58am EDT

Syngene International Ltd : Syngene International closes deal with Strand Life Sciences to purchase systems biology and pharma services practice .Financial details of the deal were not disclosed.

Epizyme collaborates with Foundation Medicine for tazemetostat phase 2 clinical trial

Wednesday, 21 Sep 2016 06:30am EDT

Epizyme Inc[EPZM.O] : Epizyme establishes collaboration with Foundation Medicine to support tazemetostat phase 2 clinical trial . Collaboration agreement with Foundation Medicine to support patient identification and enrollment for Epizyme's ongoing phase 2 clinical trial of tazemetostat . Early clinical data suggest tazemetostat has encouraging clinical activity and favorable safety profile in patients with relapsed,refractory NHL .Plans to initiate additional clinical trials of tazemetostat in 2016.

Epizyme collaborates with Foundation Medicine for tazemetostat phase 2 clinical trial

Wednesday, 21 Sep 2016 06:30am EDT

Epizyme Inc[EPZM.O] : Epizyme establishes collaboration with Foundation Medicine to support tazemetostat phase 2 clinical trial . Collaboration agreement with Foundation Medicine to support patient identification and enrollment for Epizyme's ongoing phase 2 clinical trial of tazemetostat . Early clinical data suggest tazemetostat has encouraging clinical activity and favorable safety profile in patients with relapsed,refractory NHL .Plans to initiate additional clinical trials of tazemetostat in 2016.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary